RxBlog

  • rxblog
    RxBlog is a simple weblog dedicatd to pharmaceutical news and drug information.
  • RxBlog (tm) com/net
    Is a Trademark

Pages

Sponsor Media

Simple

Sponsor Links

RxBlog Blogroll


  • rxblog.com qr code
  • Pfizer
    Our purpose is helping people live longer, healthier, happier lives. Our route to that purpose is through discovering and developing breakthrough medicines; providing information on prevention, wellness, and treatment.
  • Schering-Plough
    We aspire to earn the trust of doctors, patients and customers by providing a steady flow of innovative, science-based medicines and services that improve the health and well-being of people around the world.
  • Wyeth
    Wyeth pharmaceutical company brings health care products, medicines and vaccines that aim to improve lives and deliver value to customers.
  • Novartis
    Novartis is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and to enhance the quality of life.
  • GlaxoSmithKline
    Headquartered in the UK and with operations based in the US, we are one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
  • AstraZeneca
    One of the world's leading pharmaceutical companies providing effective prescription drugs and innovative prescription medicines in many important therapeutic areas.
  • Merck
    A global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs.
Subscribe to this blog's feed

« Introgen: ADVEXIN Molecular Targeted Therapy Is Active in Multiple Cancers | Main | Austrian Patent Office Rules in Pfizer's Favor, Ranbaxy Product Would Infringe Basic Lipitor Patent »

Inovio Biomedical acquires Valentis' DNA delivery assets

Inovio Biomedical Corp. (INO.A) on Tuesday said it acquired certain DNA delivery and expression assets from Valentis Inc. (VLTS.O: Quote, Profile, Research) for $860,000 to enhance its overall gene delivery technology platform.

The biomedical company said $300,000 from the total deal price was offset by the cancellation of an outstanding debt Valentis owed to Inovio. The acquisition includes Valentis' DNAvax polymer delivery system and GeneSwitch gene regulation technology.
Via: Reuters
Via: Wires

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341cce4453ef00d8356b6feb69e2

Listed below are links to weblogs that reference Inovio Biomedical acquires Valentis' DNA delivery assets:

Comments